ACAD
36.32
+0.49
+1.37%
AEMD
0.967
-0.013
-1.2857%
APRI
1.81
-0.01
-0.55%
ARNA
27.29
-0.02
-0.07%
ATEC
4.18
+0.06
+1.46%
CNAT
5.104
+0.094
+1.8802%
CRXM
0.137
+0.034
+32.9767%
CYTX
0.485
+0.02
+4.301%
DXCM
44.9
-0.08
-0.18%
GNMK
7.86
+0.02
+0.26%
HALO
17.84
+0.07
+0.39%
ILMN
209.63
+4.45
+2.17%
INNV
0.087
0.00
0.00%
INO
6.3
+0.05
+0.80%
ISCO
1.65
+0.11
+7.14%
ISIS
57.56
0.00
0.00%
LGND
144.7
+1.35
+0.94%
LPTN
2.93
-2.93
-100.00%
MBVX
0.71
-0.03
-4.03%
MEIP
2.63
+0.01
+0.38%
MNOV
6.15
-0.04
-0.65%
MRTX
15.832
+0.282
+1.8109%
MSTX
0.13
-0.01
0.00%
NBIX
59.406
+0.446
+0.756%
NUVA
55.32
+0.75
+1.37%
ONCS
1.26
-0.03
-2.33%
ONVO
1.629
+0.229
+16.3857%
OREX
1.79
-0.03
-1.65%
OTIC
3.425
-0.05
-1.439%
QDEL
41.65
-0.3
-0.72%
RCPT
231.96
0.00
0.00%
RGLS
1.22
-0.03
-2.40%
RMD
79.29
+0.5
+0.63%
SCIE
0
0.00
0.00%
SPHS
2.321
+0.081
+3.616%
SRNE
2.73
+0.23
+9.20%
TROV
0.807
-0.002
-0.2472%
VICL
2.34
-0.04
-1.68%
VOLC
18
0.00
0.00%
ZGNX
40
+0.35
+0.88%
ACAD
36.32
+0.49
+1.37%
AEMD
0.967
-0.013
-1.2857%
APRI
1.81
-0.01
-0.55%
ARNA
27.29
-0.02
-0.07%
ATEC
4.18
+0.06
+1.46%
CNAT
5.104
+0.094
+1.8802%
CRXM
0.137
+0.034
+32.9767%
CYTX
0.485
+0.02
+4.301%
DXCM
44.9
-0.08
-0.18%
GNMK
7.86
+0.02
+0.26%
HALO
17.84
+0.07
+0.39%
ILMN
209.63
+4.45
+2.17%
INNV
0.087
0.00
0.00%
INO
6.3
+0.05
+0.80%
ISCO
1.65
+0.11
+7.14%
ISIS
57.56
0.00
0.00%
LGND
144.7
+1.35
+0.94%
LPTN
2.93
-2.93
-100.00%
MBVX
0.71
-0.03
-4.03%
MEIP
2.63
+0.01
+0.38%
MNOV
6.15
-0.04
-0.65%
MRTX
15.832
+0.282
+1.8109%
MSTX
0.13
-0.01
0.00%
NBIX
59.406
+0.446
+0.756%
NUVA
55.32
+0.75
+1.37%
ONCS
1.26
-0.03
-2.33%
ONVO
1.629
+0.229
+16.3857%
OREX
1.79
-0.03
-1.65%
OTIC
3.425
-0.05
-1.439%
QDEL
41.65
-0.3
-0.72%
RCPT
231.96
0.00
0.00%
RGLS
1.22
-0.03
-2.40%
RMD
79.29
+0.5
+0.63%
SCIE
0
0.00
0.00%
SPHS
2.321
+0.081
+3.616%
SRNE
2.73
+0.23
+9.20%
TROV
0.807
-0.002
-0.2472%
VICL
2.34
-0.04
-1.68%
VOLC
18
0.00
0.00%
ZGNX
40
+0.35
+0.88%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Representative Scott Peters Visits Avelas Biosciences

November 20, 2015 – 11:46 am

Congressman sees first-hand San Diego biotech and medical innovations

SAN DIEGO, Nov. 20, 2015 /PRNewswire/ — Today U.S. Congressional Representative (CA-52) Scott Peters toured Avelas Biosciences, a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment. During the visit, he met with local entrepreneurs from Avelas, Avalon Ventures and COI Pharmaceuticals as well as medical innovators from UCSD.

“It was a privilege to host Representative Peters at Avelas Biosciences today,” said Carmine Stengone, president and CEO of Avelas Biosciences. “We appreciate all the work he has done to support medical innovation and the opportunity to showcase our disruptive technology designed to improve cancer surgery and therapeutic targeting. Avelas is a true San Diego biotech innovation story, with San Diego technology, investors, entrepreneurs and medical innovators.”

Avelas Biosciences was founded by Avalon Ventures on technology from the lab of Nobel laureate Roger Y. Tsien, Ph.D., professor of chemistry, biochemistry and pharmacology at UC San Diego. It is headquartered at COI Pharmaceuticals, Avalon’s Community Of Innovation. Avelas is developing AVB-620, a fluorescent, cancer “illuminator” that is designed to enable surgeons to distinguish tumor tissue from normal during surgery. AVB-620 is in clinical trials for breast cancer under the leadership of Anne Wallace, M.D., director of the Comprehensive Breast Health Center at Moores Cancer Center at UC San Diego Health.

“At UC San Diego, we are committed to translating science discovered in the lab to our cancer patients, to providing access to new and often dramatic technologies through early clinical trials,” said Dr. Wallace. “This partnership between science, clinicians and the community allows us to help bring forward improvements in cancer care for patients here and around the world.”

Representative Peters stated, “Avelas, Avalon and the Community Of Innovation are more examples of San Diego’s leadership in the fields of bioscience and biotechnology. The collaborative approach I saw here today is what sets San Diego apart and why the research performed in San Diego is recognized around the world.”

Earlier this month, Representative Peters was honored by the Healthcare Leadership Council as a “Champion of Healthcare Innovation” in recognition of his support of patient-centered medical progress.

About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. Lead candidate AVB-620 is in phase 1b trials in up to 39 breast cancer patients, assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. Avelas was founded by Avalon Ventures on technology from Nobel laureate Roger Y. Tsien, Ph.D.  For additional information, please visit www.avelasbio.com.

University of California Disclaimer
The information stated above was prepared by Avelas Biosciences Inc. and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of Avelas Biosciences, Inc. or any of its products, by The Regents of the University of California, its officers, agents and employees.

 

SOURCE Avelas Biosciences

West Coast Bio Roundup: Shkreli, T4 Diabetes, Cella-Done, A16Z+Bio

November 20, 2015 – 5:42 am

So much for lying low. Investors led by Martin Shkreli have bought a majority of the shares of failed South San Francisco, CA-based KaloBios Pharmaceuticals, which has been in dire straits for some…

[[Click headline to continue reading.]]

Salk Recruits Nobel Laureate Liz Blackburn as First Woman President

November 19, 2015 – 1:08 pm

The Salk Institute has named Elizabeth Blackburn, a Nobel laureate and UC San Francisco professor of biochemistry and biophysics, as its first woman president. Blackburn has been a non-resident…

[[Click headline to continue reading.]]

Natera Announces the Appointment of Jimmy Lin as Chief Scientific Officer for Oncology

November 19, 2015 – 7:00 am

SAN CARLOS, Calif., Nov. 19, 2015 /PRNewswire/ — Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Jimmy Lin, MD, PhD, MHS has been appointed as Chief Scientific Officer for Oncology. Dr. Jimmy Cheng-Ho Lin joins Natera coming from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute at the National Institutes of Health. Previously, at Johns Hopkins, Dr. Lin led the computational analysis of the first ever exome sequencing studies in cancer, including breast, colorectal, pancreatic, glioblastoma, medulloblastoma, and melanoma.

In addition, Dr. Lin is the Founder and President of Rare Genomics Institute, the world’s first platform to enable any community to leverage cutting-edge biotechnology to advance understanding of any rare disease. Dr. Lin is a 2012 TED fellow and has spoken at many TED and TEDx events. He has numerous publications in Science, Nature, Cell, Nature Genetics, and Nature Biotechnology, and has been featured in multiple outlets including Forbes, Bloomberg Businessweek, Wall Street Journal, New York Times, Washington Post, the Huffington Post, and the Financial Times. Dr. Lin holds an MHS in Bioinformatics, a PhD in Cellular and Molecular Medicine, and an MD from Johns Hopkins University as well dual majors in Cognitive Science and Molecular Biophysics and Biochemistry from Yale University.

“We are pleased to announce that Jimmy Lin has joined Natera to lead our scientific research program. His contribution to the field of oncology research includes ground-breaking cancer genome sequencing efforts,” said Matthew Rabinowitz, Ph.D., CEO of Natera. “Jimmy will be driving all aspects of our oncology development program, from sample collection efforts and clinical trials, to panel design and bioinformatics.”

About Natera
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum™ pre-implantation genetic test for embryo selection during IVF; the Anora™ miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama™ non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.

Contacts
Natera, Inc.
Mike Brophy, Investor Relations, 650-249-9091 x 1471
mbrophy@natera.com

Michael Hromadik, Media Relations, 858-442-2215
mhromadik@natera.com

Logo – http://photos.prnewswire.com/prnh/20151112/286881LOGO

 

 

SOURCE Natera, Inc.

Peeking into the Underwater World of Leopard Seals

November 19, 2015 – 7:00 am

In the pristine wilds of the Antarctic, the mysterious leopard seal rules the animal kingdom. This polar bear-sized top predator has razor-sharp canine teeth and the ability to greatly impact or even decimate entir…

Peeking into the Underwater World of Leopard Seals

November 19, 2015 – 7:00 am

In the pristine wilds of the Antarctic, the mysterious leopard seal rules the animal kingdom. This polar bear-sized top predator has razor-sharp canine teeth and the ability to greatly impact or even decimate entir…

Peeking into the Underwater World of Leopard Seals

November 19, 2015 – 7:00 am

In the pristine wilds of the Antarctic, the mysterious leopard seal rules the animal kingdom. This polar bear-sized top predator has razor-sharp canine teeth and the ability to greatly impact or even decimate entir…

Natera Announces the Appointment of Jimmy Lin as Chief Scientific Officer for Oncology

November 19, 2015 – 7:00 am

SAN CARLOS, Calif., Nov. 19, 2015 /PRNewswire/ — Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Jimmy Lin, MD, PhD, MHS has been appointed as Chief Scientific Officer for Oncology. Dr. Jimmy Cheng-Ho Lin joins Natera coming from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute at the National Institutes of Health. Previously, at Johns Hopkins, Dr. Lin led the computational analysis of the first ever exome sequencing studies in cancer, including breast, colorectal, pancreatic, glioblastoma, medulloblastoma, and melanoma.

In addition, Dr. Lin is the Founder and President of Rare Genomics Institute, the world’s first platform to enable any community to leverage cutting-edge biotechnology to advance understanding of any rare disease. Dr. Lin is a 2012 TED fellow and has spoken at many TED and TEDx events. He has numerous publications in Science, Nature, Cell, Nature Genetics, and Nature Biotechnology, and has been featured in multiple outlets including Forbes, Bloomberg Businessweek, Wall Street Journal, New York Times, Washington Post, the Huffington Post, and the Financial Times. Dr. Lin holds an MHS in Bioinformatics, a PhD in Cellular and Molecular Medicine, and an MD from Johns Hopkins University as well dual majors in Cognitive Science and Molecular Biophysics and Biochemistry from Yale University.

“We are pleased to announce that Jimmy Lin has joined Natera to lead our scientific research program. His contribution to the field of oncology research includes ground-breaking cancer genome sequencing efforts,” said Matthew Rabinowitz, Ph.D., CEO of Natera. “Jimmy will be driving all aspects of our oncology development program, from sample collection efforts and clinical trials, to panel design and bioinformatics.”

About Natera
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum™ pre-implantation genetic test for embryo selection during IVF; the Anora™ miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama™ non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.

Contacts
Natera, Inc.
Mike Brophy, Investor Relations, 650-249-9091 x 1471
mbrophy@natera.com

Michael Hromadik, Media Relations, 858-442-2215
mhromadik@natera.com

Logo – http://photos.prnewswire.com/prnh/20151112/286881LOGO

 

 

SOURCE Natera, Inc.

Peeking into the Underwater World of Leopard Seals

November 19, 2015 – 7:00 am

In the pristine wilds of the Antarctic, the mysterious leopard seal rules the animal kingdom. This polar bear-sized top predator has razor-sharp canine teeth and the ability to greatly impact or even decimate entir…

Peeking into the Underwater World of Leopard Seals

November 19, 2015 – 7:00 am

In the pristine wilds of the Antarctic, the mysterious leopard seal rules the animal kingdom. This polar bear-sized top predator has razor-sharp canine teeth and the ability to greatly impact or even decimate entir…